Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

Novavax (NVAX) ended the recent trading session at $8.67, demonstrating a +1.17% change from the preceding day's closing price. This change outpaced the S&P 500's 0.41% gain on the day. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 0.31%. Shares of the vaccine maker have appreciated by 14.73% over the course of the past month, outperforming the Medical sector's loss of 0.38%, and the S&P 500's gain of 3.15%.Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.26, signifying a 65.79% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $67 million, showing a 20.72% drop compared to the year-ago quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.68 per share and revenue of $1.03 billion, indicating changes of +317.89% and +51.52%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Novavax is currently sporting a Zacks Rank of #3 (Hold). In the context of valuation, Novavax is at present trading with a Forward P/E ratio of 3.2. This valuation marks a discount compared to its industry average Forward P/E of 18.79. We can additionally observe that NVAX currently boasts a PEG ratio of 0.11. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 32% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. 7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novavax, Inc. (NVAX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks